Presentation is loading. Please wait.

Presentation is loading. Please wait.

Fit for treatment Confirmed mCRC Request RAS Yes Liver only disease?

Published byΑμάλθεια Μεταξάς Modified over 6 years ago

Similar presentations

Presentation on theme: "Fit for treatment Confirmed mCRC Request RAS Yes Liver only disease?"— Presentation transcript:

1 Exeter and Torbay Algorithm for systemic treatment of metastatic Colorectal Cancer March 2015
Fit for treatment Confirmed mCRC Request RAS Yes Liver only disease? Neo-adjuvant treatment (NICE TA176) RAS status Wild-type Mutant Fit for Irinotecan? Fit for Irinotecan? Yes No Yes No 1st Irinotecan + FP + Cetuximab Capecitabine Irinotecan + FP Capecitabine 2nd Oxaliplatin + FP + Bevacizumab Oxaliplatin + FP + Bevacizumab Oxaliplatin + FP + Bevacizumab Oxaliplatin + FP + Bevacizumab 3rd Mitomycin + FP Cetuximab or Panitumumab Mitomycin + FP ?Irinotecan + FP if fit

Download ppt "Fit for treatment Confirmed mCRC Request RAS Yes Liver only disease?"

Similar presentations

FOLFOXIRI plus bevacizumab (bev) vs FOLFIRI plus bev

FOLFOXIRI plus bevacizumab (bev) vs FOLFIRI plus bev
Direct Cost Survival Analysis of Treatment of Metastatic Colorectal Cancer Yu-Ning Wong 1, Neal J. Meropol 1, Daniel Sargent 2, Richard Goldberg 3, J.

Direct Cost Survival Analysis of Treatment of Metastatic Colorectal Cancer Yu-Ning Wong 1, Neal J. Meropol 1, Daniel Sargent 2, Richard Goldberg 3, J.
Aakash H. Gajjar, MD, FACS Assistant Professor of Surgery Colon & Rectal Surgery University of Texas Medical Branch Galveston, Texas February 10 th, 2014.

Aakash H. Gajjar, MD, FACS Assistant Professor of Surgery Colon & Rectal Surgery University of Texas Medical Branch Galveston, Texas February 10 th, 2014.
KRAS Status in Response to Cetuximab

KRAS Status in Response to Cetuximab
BOPA 2009 Clinical Update: Colorectal Cancer Dr Nick Maisey.

BOPA 2009 Clinical Update: Colorectal Cancer Dr Nick Maisey.
CALGB/SWOG 80405: Phase III trial of FOLFIRI or FOLFOX with Bevacizumab or Cetuximab for patients w/ KRAS wild type untreated metastatic adenocarcinoma.

CALGB/SWOG 80405: Phase III trial of FOLFIRI or FOLFOX with Bevacizumab or Cetuximab for patients w/ KRAS wild type untreated metastatic adenocarcinoma.
Individualizing Therapy for Gastrointestinal Malignancies 2010 Update

Individualizing Therapy for Gastrointestinal Malignancies 2010 Update
Post G.I. ASCO Update: Colorectal Cancer Ronald Burkes, M.D.

Post G.I. ASCO Update: Colorectal Cancer Ronald Burkes, M.D.
Regulatory Background and Past FDA Approvals in Colorectal Cancer Amna Ibrahim M.D DODP, FDA.

Regulatory Background and Past FDA Approvals in Colorectal Cancer Amna Ibrahim M.D DODP, FDA.
Colorectal Cancer Center Jena 18.05.2011 Introduction In Germany, there are currently approximately 70 000 newly diagnosed patients with colorectal carcinoma.

Colorectal Cancer Center Jena Introduction In Germany, there are currently approximately newly diagnosed patients with colorectal carcinoma.
Colon Cancer Daniel A. Nikcevich, MD, PhD Duluth Clinic Cancer Center January 26, 2009.

Colon Cancer Daniel A. Nikcevich, MD, PhD Duluth Clinic Cancer Center January 26, 2009.
Phase III study of first-line XELOX plus bevacizumab (BEV) for 6 cycles followed by XELOX plus BEV or single agent (s/a) BEV as maintenance therapy in.

Phase III study of first-line XELOX plus bevacizumab (BEV) for 6 cycles followed by XELOX plus BEV or single agent (s/a) BEV as maintenance therapy in.
Treatment options depend on the following: – The stage of the cancer – Whether the cancer has recurred – The patient’s general health.

Treatment options depend on the following: – The stage of the cancer – Whether the cancer has recurred – The patient’s general health.
Clinicaloptions.com/oncology Expert Insight Into the First-line Treatment of Metastatic Colorectal Cancer N016966: Efficacy Results  PFS significantly.

Clinicaloptions.com/oncology Expert Insight Into the First-line Treatment of Metastatic Colorectal Cancer N016966: Efficacy Results  PFS significantly.
Paolo Marchetti Oncologia Medica Ospedale Sant’Andrea & IDI IRCCS Roma Higher drug costs and healthcare savings: a true conflict of interest 1 Oncology:

Paolo Marchetti Oncologia Medica Ospedale Sant’Andrea & IDI IRCCS Roma Higher drug costs and healthcare savings: a true conflict of interest 1 Oncology:
The Colorectal Cancer Center Jena Gharbi A, Settmacher U. Department of General, Visceral and Vascular Surgery, Friedrich-Schiller-University Jena 18.05.2011.

The Colorectal Cancer Center Jena Gharbi A, Settmacher U. Department of General, Visceral and Vascular Surgery, Friedrich-Schiller-University Jena
Results of the X-PECT Study: A phase III randomized double-blind placebo-controlled study of perifosine plus capecitabine (P-CAP) vs. placebo plus capecitabine.

Results of the X-PECT Study: A phase III randomized double-blind placebo-controlled study of perifosine plus capecitabine (P-CAP) vs. placebo plus capecitabine.
Systemic Treatment of Metastatic Colorectal Cancer: Living with a Moving Landscape Neal J. Meropol, MD Fox Chase Cancer Center May 16, 2005.

Systemic Treatment of Metastatic Colorectal Cancer: Living with a Moving Landscape Neal J. Meropol, MD Fox Chase Cancer Center May 16, 2005.
Minimal versus Intense Upfront Systemic Therapy in Metastatic Colorectal Cancer Paulo M. Hoff, MD, FACP Hospital Sirio Libanes Sao Paulo, Brazil Centro.

Minimal versus Intense Upfront Systemic Therapy in Metastatic Colorectal Cancer Paulo M. Hoff, MD, FACP Hospital Sirio Libanes Sao Paulo, Brazil Centro.
Dr Francis Daniel, MB. ChB, FFR-RCSI, FRCR. Consultant in Clinical Oncology www.bowelcancerwest.org.uk.

Dr Francis Daniel, MB. ChB, FFR-RCSI, FRCR. Consultant in Clinical Oncology

Similar presentations

Ads by Google